close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

53.81 +0.57 (+1.07%)
Official Closing Price Updated: 4:15 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition
BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study. 
Via Benzinga
BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival
The company ran an exploratory analysis of its drug, Attruby, in patients with cardiomyopathy due to TTR amyloidosis. 
Via Investor's Business Daily
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows Strong Technical Setup for Potential Breakout
BridgeBio Pharma (BBIO) shows strong technicals with a perfect 10 rating. Currently in a consolidation pattern, it may be poised for a breakout above resistance, offering a potential entry for... 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
BRIDGEBIO PHARMA INC (NASDAQ:BBIO) Shows Strong Technical Breakout Potential with High Momentum and Consolidation Setup
BridgeBio Pharma (BBIO) shows strong breakout potential with a perfect Technical Rating of 10 and Setup Rating of 9, signaling robust momentum and consolidation. Ideal for traders eyeing... 
Via Chartmill
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For April 29, 2025
 
Via Benzinga
A Look Ahead: BridgeBio Pharma's Earnings Forecast
 
Via Benzinga
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Via The Motley Fool
BridgeBio Pharma Inc (NASDAQ:BBIO) Shares Drop 11% After Q2 2025 Earnings Miss Despite Revenue Beat
BridgeBio Pharma reports mixed Q2 2025 results with revenue beating estimates but EPS missing, causing an 11% stock drop. Strong prescription growth contrasts with profitability concerns. 
Via Chartmill
Topics Earnings
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Is Pfizer Stock a Yield Trap?
Via The Motley Fool
Topics Intellectual Property
Earnings Scheduled For February 20, 2025
 
Via Benzinga
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
The Smart Money Is Buying These 10 Stocks
 
Via Benzinga
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility. 
Via Benzinga
Topics World Trade
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market. 
Via Investor's Business Daily
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it. 
Via Benzinga
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Top 4 Health Care Stocks You May Want To Dump In Q1
 
Via Benzinga
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
 
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today